Pluri Inc. Faces Delisting Concerns
Ticker: PLUR · Form: 8-K · Filed: May 31, 2024 · CIK: 1158780
| Field | Detail |
|---|---|
| Company | Pluri Inc. (PLUR) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $2,500,000, $35 million, $500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Pluri Inc. might get delisted, trading could be affected.
AI Summary
Pluri Inc. filed an 8-K on May 31, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indicates a potential transfer of listing, with the earliest event reported on May 28, 2024. The company, formerly known as Pluristem Therapeutics Inc., is incorporated in Nevada and operates in the biological products sector.
Why It Matters
This filing signals potential financial distress or non-compliance with stock exchange rules, which could significantly impact investor confidence and the company's ability to trade publicly.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards indicates a severe risk to the company's continued public trading status.
Key Players & Entities
- Pluri Inc. (company) — Registrant
- Pluristem Therapeutics Inc. (company) — Former company name
- May 28, 2024 (date) — Earliest event reported date
- May 31, 2024 (date) — Filing date
FAQ
What specific rule or standard has Pluri Inc. failed to satisfy, leading to this notice?
The filing does not specify the exact rule or standard that Pluri Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the nature of the potential 'transfer of listing' mentioned in the filing?
The filing mentions a 'Transfer of Listing' as an item of information, but does not provide details on the specific exchange or the process involved.
When was the earliest event reported that is relevant to this 8-K filing?
The earliest event reported is dated May 28, 2024.
What was Pluri Inc. formerly known as?
Pluri Inc. was formerly known as Pluristem Therapeutics Inc.
In which state is Pluri Inc. incorporated?
Pluri Inc. is incorporated in Nevada.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 17.3 · Accepted 2024-05-31 16:05:18
Key Financial Figures
- $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
- $2,500,000 — es the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued l
- $35 million — value of listed securities of at least $35 million or net income of $500,000 from continui
- $500,000 — f at least $35 million or net income of $500,000 from continuing operations in the most
Filing Documents
- ea0207110-8k_pluriinc.htm (8-K) — 31KB
- 0001213900-24-048443.txt ( ) — 202KB
- plur-20240528.xsd (EX-101.SCH) — 3KB
- plur-20240528_lab.xml (EX-101.LAB) — 33KB
- plur-20240528_pre.xml (EX-101.PRE) — 22KB
- ea0207110-8k_pluriinc_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its potentially regaining compliance with Nasdaq's continued listing requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise re
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: May 31, 2024 By: /s/ Chen Franco-Yehuda Name: Chen Franco-Yehuda Title: Chief Financial Officer 2